Renaissance Technologies
RNTX

Renaissance Technologies’s Rein Therapeutics RNTX Stock Holding History

Renaissance Technologies’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9K Buy
24,500
+1,800
+8% +$2.23K ﹤0.01% 3138
2025
Q4 		$26.3K Buy
22,700
+4,402
+24% +$6.07K ﹤0.01% 3130
2025
Q3 		$21K Buy
+18,298
New +$23.2K ﹤0.01% 3421
2024
Q4 		– Sell
-13,164
Closed -$46.6K – 3981
2024
Q3 		$46.6K Sell
13,164
-11,700
-47% -$31.3K ﹤0.01% 3352
2024
Q2 		$68.9K Sell
24,864
-20,200
-45% -$83K ﹤0.01% 3245
2024
Q1 		$299K Buy
45,064
+17,045
+61% +$81.6K ﹤0.01% 3091
2023
Q4 		$85K Buy
28,019
+9,055
+48% +$17.7K ﹤0.01% 3345
2023
Q3 		$29K Buy
18,964
+3,100
+20% +$5.26K ﹤0.01% 3478
2023
Q2 		$28K Buy
15,864
+3,200
+25% +$4.93K ﹤0.01% 3720
2023
Q1 		$16K Buy
12,664
+2,100
+20% +$4.5K ﹤0.01% 3851
2022
Q4 		$25K Buy
10,564
+1,029
+11% +$3.46K ﹤0.01% 3931
2022
Q3 		$39K Buy
9,535
+3,775
+66% +$15.9K ﹤0.01% 3813
2022
Q2 		$30K Buy
5,760
+2,835
+97% +$26K ﹤0.01% 4080
2022
Q1 		$30K Sell
2,925
-20,597
-88% -$186K ﹤0.01% 3971
2021
Q4 		$265K Sell
23,522
-13,214
-36% -$204K ﹤0.01% 3398
2021
Q3 		$749K Sell
36,736
-14,820
-29% -$325K ﹤0.01% 2705
2021
Q2 		$1.29M Sell
51,556
-10,969
-18% -$274K ﹤0.01% 2532
2021
Q1 		$1.79M Buy
62,525
+30,806
+97% +$1.06M ﹤0.01% 2295
2020
Q4 		$660K Sell
31,719
-28,502
-47% -$712K ﹤0.01% 2705
2020
Q3 		$1.55M Sell
60,221
-8,973
-13% -$211K ﹤0.01% 2270
2020
Q2 		$1.63M Buy
69,194
+45,335
+190% +$739K ﹤0.01% 2288
2020
Q1 		$158K Sell
23,859
-695
-3% -$8.37K ﹤0.01% 3143
2019
Q4 		$281K Buy
24,554
+7,542
+44% +$74.4K ﹤0.01% 3088
2019
Q3 		$228K Buy
17,012
+7,185
+73% +$99.4K ﹤0.01% 3111
2019
Q2 		$142K Buy
9,827
+2,661
+37% +$69.8K ﹤0.01% 3357
2019
Q1 		$279K Sell
7,166
-2,883
-29% -$89.8K ﹤0.01% 3115
2018
Q4 		$169K Buy
10,049
+7,562
+304% +$304K ﹤0.01% 3163
2018
Q3 		$137K Buy
+2,487
New +$167K ﹤0.01% 3211

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Renaissance Technologies's RNTX Position: Q1 2026 in Review

Renaissance Technologies increased its Rein Therapeutics (RNTX) stake by 7.9% in Q1 2026, buying an estimated $2.23K and bringing the position to 24,500 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

Renaissance Technologies first reported a position in RNTX in Q3 2018 and has held it in 28 quarters since. The position peaked at $1.79M in Q1 2021. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Renaissance Technologies held 24,500 shares of Rein Therapeutics worth $31.9K as of Q1 2026.
  • Renaissance Technologies bought 1,800 Rein Therapeutics shares in Q1 2026, an estimated $2.23K.
  • Rein Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3138 holding.
  • Renaissance Technologies first reported a position in Rein Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • Renaissance Technologies's Rein Therapeutics position peaked at $1.79M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.